INCB3619 (subcutaneous injection, 60 mg/kg/d, 14 d) exhibits antitumor activity and sensitizes tumors to Gefitinib (HY-50895) in A549 xenografted BALB/c nu/nu mouse model[1].
| Animal Model: | BALB/c nu/nu mouse model of A549 xenograft |
| Dosage: | 50, 60 mg/kg |
| Administration: | subcutaneous injection, daily, 14 d |
| Result: | Significant tumor growth inhibition and delay at 60 mg/kg dose, less active effect at 50 mg/kg. |
